hotspot -WSS

hotspot

author：hotspot 2025-09-30 23:39:03 - browse：5772

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： The untold story of TV’s first prescription drug ad

WSS

IVF doctors demand details after CooperSurgical lawsuit

Microsoft's Peter Lee: Generative AI could help doctors be more human

Longer MASH drug regimen improved liver, Akero study finds

Illumina to lay off 10% of research and development team

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Harvard's David Sinclair gets blowback over aging

leisure time

hotspot

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

The public health thinking behind the CDC’s new Covid guidance

Dobbs anniversary: the lost opportunity of abortion as health care

Ozempic has benefits for kidney disease as well as diabetes

Heart attack and stroke risk calculators need revising

Harvard's David Sinclair gets blowback over aging

Drug repurposing or repositioning? The language matters

Harvard's David Sinclair gets blowback over aging

Medicare details structure of new drug price negotiation program

Synthetic human embryos? Researchers say term is overblown

explore

Readout Newsletter: BridgeBio, Akero, and human embryo models

Thousands protest in Iraq for a second day over burning of Quran in Sweden

Longer MASH drug regimen improved liver, Akero study finds

Ukrainian soldiers say they owe lives to US

State of the Union pitch: Bigger Medicare drug price negotiations

The simple reason for the increase in autism diagnosis

focus

hotspot

knowledge

hotspot